Nanocapsulated Rift Valley fever vaccine candidates and relative immunological and histopathological reactivity in out bred sWiss mice

13Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

The present work aimed to compare the potentials of Alum and CAP as adjuvants and related immune response to RVFV vaccines candidates inactivated using different inactivants namely, Formalin, Beta-Propiolactone (BPL) and Ascorbic acid (AA). Potency (ED50) of inactivated vaccines was arranged in the order of BPL (0.006), AA (0.0024), and formalin (0.011) respectively. Data recorded revealed that BPL inactivated showed a fast inactivating efficacy and inactivation time was arranged as BPL (2 hrs) followed by formalin (6 hrs) and AA (within 24hrs). BPL - CAP adjuvanted RVFV vaccine showed a higher and long durative antibody level than that detected post immunization with the other RFVF vaccine formulations either alum or CAP adjuvanted vaccines. Limited histopathological changes detected post CAP adjuvanted vaccine compared with that detected post Alum adjuvanted one was detected. © 2011 Abd el-Razek NEE, et al.

Cite

CITATION STYLE

APA

Abd el-Razek, N. E. E. D., Shoman, S. A., & Mohamed, A. F. (2011). Nanocapsulated Rift Valley fever vaccine candidates and relative immunological and histopathological reactivity in out bred sWiss mice. Journal of Vaccines and Vaccination, 2(1). https://doi.org/10.4172/2157-7560.1000115

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free